New vaccine aims to stop pancreatic cancer return after surgery
NCT ID NCT06353646
First seen Feb 15, 2026 · Last updated May 21, 2026 · Updated 16 times
Summary
This study tests a personalized cancer vaccine (XH001) given after surgery for pancreatic cancer. The vaccine is designed to train the immune system to recognize and attack any remaining cancer cells. It is given along with standard immunotherapy and chemotherapy. The goal is to see if this combination can prevent the cancer from coming back. The trial will include 28 adults who have had their pancreatic cancer surgically removed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.